NO20033966L - Fremgangsmåte for oppnåelse av mikropartikler inneholdende H+, K+-ATP-ase-inhibitorer - Google Patents

Fremgangsmåte for oppnåelse av mikropartikler inneholdende H+, K+-ATP-ase-inhibitorer

Info

Publication number
NO20033966L
NO20033966L NO20033966A NO20033966A NO20033966L NO 20033966 L NO20033966 L NO 20033966L NO 20033966 A NO20033966 A NO 20033966A NO 20033966 A NO20033966 A NO 20033966A NO 20033966 L NO20033966 L NO 20033966L
Authority
NO
Norway
Prior art keywords
sup
atp
microparticles containing
ase inhibitors
obtaining microparticles
Prior art date
Application number
NO20033966A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033966D0 (no
Inventor
Haakan Glad
Malin Soederbom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20033966D0 publication Critical patent/NO20033966D0/no
Publication of NO20033966L publication Critical patent/NO20033966L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • General Preparation And Processing Of Foods (AREA)
NO20033966A 2001-03-09 2003-09-08 Fremgangsmåte for oppnåelse av mikropartikler inneholdende H+, K+-ATP-ase-inhibitorer NO20033966L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100822A SE0100822D0 (sv) 2001-03-09 2001-03-09 Method II to obtain microparticles
PCT/SE2002/000400 WO2002072071A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor

Publications (2)

Publication Number Publication Date
NO20033966D0 NO20033966D0 (no) 2003-09-08
NO20033966L true NO20033966L (no) 2003-11-03

Family

ID=20283293

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033966A NO20033966L (no) 2001-03-09 2003-09-08 Fremgangsmåte for oppnåelse av mikropartikler inneholdende H+, K+-ATP-ase-inhibitorer

Country Status (21)

Country Link
US (2) US20040101565A1 (https=)
EP (1) EP1370243B1 (https=)
JP (1) JP2004522796A (https=)
KR (1) KR20030081506A (https=)
CN (1) CN1507343A (https=)
AT (1) ATE400253T1 (https=)
AU (1) AU2002235101B8 (https=)
BR (1) BR0207827A (https=)
CA (1) CA2440163A1 (https=)
DE (1) DE60227488D1 (https=)
DK (1) DK1370243T3 (https=)
ES (1) ES2307722T3 (https=)
IL (1) IL157467A0 (https=)
MX (1) MXPA03007887A (https=)
NO (1) NO20033966L (https=)
NZ (1) NZ527997A (https=)
PT (1) PT1370243E (https=)
SE (1) SE0100822D0 (https=)
SI (1) SI1370243T1 (https=)
WO (1) WO2002072071A1 (https=)
ZA (1) ZA200306614B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2518780C (en) 2003-03-12 2014-05-13 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
US20070207266A1 (en) * 2006-02-15 2007-09-06 Lemke Harald K Method and apparatus for coating particulates utilizing physical vapor deposition
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
US20090087569A1 (en) * 2007-09-27 2009-04-02 Fenchem Enterprises Ltd. Methods for Preparing Highly Stable Hyaluronic Acid
IT1401284B1 (it) * 2010-08-06 2013-07-18 Valpharma S P A Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) * 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3565475D1 (en) * 1984-04-07 1988-11-17 Bayer Ag Process and apparatus for the production of granules
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE3909455A1 (de) * 1989-03-22 1990-09-27 Hoechst Ag Verfahren zur herstellung von wasserdispergierbaren granulaten
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE19613395A1 (de) * 1996-04-03 1997-10-09 Basf Ag Granulate hygroskopischer, wasserlöslicher Produkte
DE19733094A1 (de) * 1997-07-31 1999-02-04 Merck Patent Gmbh Formulierung auf der Basis von Ascorbinsäure mit verbesserter Farbstabilität
ATE346589T1 (de) * 1997-10-15 2006-12-15 Merck Patent Gmbh Herstellung eines direkt verpressbaren tablettierhilfsstoffes
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE500815T1 (de) * 1997-12-08 2011-03-15 Dietrich Rango Neue suppositoriumsform mit säureempfindlichem wirkstoff
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
SE0100823D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles

Also Published As

Publication number Publication date
US20080175917A1 (en) 2008-07-24
BR0207827A (pt) 2004-03-02
PT1370243E (pt) 2008-09-16
CA2440163A1 (en) 2002-09-19
SE0100822D0 (sv) 2001-03-09
WO2002072071A1 (en) 2002-09-19
AU2002235101B8 (en) 2006-08-31
ES2307722T3 (es) 2008-12-01
JP2004522796A (ja) 2004-07-29
CN1507343A (zh) 2004-06-23
US20040101565A1 (en) 2004-05-27
ZA200306614B (en) 2004-11-25
IL157467A0 (en) 2004-03-28
MXPA03007887A (es) 2003-12-04
DK1370243T3 (da) 2008-10-13
EP1370243A1 (en) 2003-12-17
ATE400253T1 (de) 2008-07-15
SI1370243T1 (sl) 2008-12-31
NZ527997A (en) 2005-02-25
HK1059896A1 (en) 2004-07-23
EP1370243B1 (en) 2008-07-09
DE60227488D1 (de) 2008-08-21
KR20030081506A (ko) 2003-10-17
AU2002235101B2 (en) 2006-07-13
NO20033966D0 (no) 2003-09-08

Similar Documents

Publication Publication Date Title
NO20033966L (no) Fremgangsmåte for oppnåelse av mikropartikler inneholdende H+, K+-ATP-ase-inhibitorer
AP2001002217A0 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
EP0931788A3 (en) Metalloprotease inhibitors
DE60205776T2 (de) Indolinon-derivative als protein-kinasehemmer
DE69936386D1 (de) Sprühgetrocknete proteinformulierungen
JO2371B1 (en) 4-phenyl-pyridine derivatives
CY1106015T1 (el) Ενα συμπυκνωμενο, υδατοδιαλυτο, κοκκωδες σκευασμα ρυθμιστη της φυτικης αναπτυξης και μεθοδοι χρησης και ιδιου
HK1046276A1 (zh) 有益的用作erk抑制剂的吡唑组合物
DE60227709D1 (de) Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
EA200300834A1 (ru) Антагонисты фактора, высвобождающего кортикотропин
CA2519432A1 (en) Pharmaceutical compositions comprising cetp inhibitors and a water-insoluble concentration-enhancing additive for the treatment of cardiovascular disease
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
DE60211769D1 (de) Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
NO20033967L (no) Fremgangsmåte for fremstilling av mikropartikler som inneholder metoprolol
IL162314A (en) Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides, processes for their preparation, pharmaceutical compositions comprising them and uses thereof
GB2409645A (en) Flower essence-containing medicaments
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
MY135375A (en) Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
MY128242A (en) Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
ATE403422T1 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2
FR2840306B1 (fr) Derives d'acide(alkyl d-mannopyranoside) uronique, des procedes pour leur preparation, ainsi que leurs applications
BR0307172A (pt) Composição farmacêutica contendo 2,2-dicloro-12-(4-clorofenil)-ácido dodecanóico
DE60209354D1 (de) Hydroxamsäure-derivate
AU2002366563A1 (en) Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application